The head and neck squamous cell carcinoma (HNSCC) market is projected to grow at a 10.5% CAGR from 2026 to 2036, driven by rising cancer incidence and new immunotherapy launches. Key emerging therapies from companies like Johnson & Johnson, BioNTech, and Genmab are expected to transform treatment options. The U.S. leads the market, with KEYTRUDA generating the highest revenue in 2025. Advances in targeted therapies and personalized medicine are also fueling growth, alongside expanding clinical trials and regulatory approvals.
Bridgewater Associates, led by Ray Dalio, disclosed a $24.4 billion stock portfolio as of June 30, 2026, with a strong focus on ETFs like SPY and IVV, which make up over 25% of holdings. The hedge fund increased its ETF positions but reduced stakes i...
Five Dividend Aristocrats—Johnson & Johnson, Procter & Gamble, McDonald's, Coca-Cola, and Automatic Data Processing—continue to demonstrate reliable dividend growth streaks of 25 years or more. Each company shows strong earnings and cash flow, suppor...
Johnson & Johnson has delivered a strong 28% total return year-to-date in 2026, outperforming major benchmarks like the S&P 500 ETF and healthcare sector ETF XLV. Despite solid second-quarter results and an upgraded full-year 2026 guidance driven by ...
Five US-listed Dividend Kings—Johnson & Johnson, Procter & Gamble, Coca-Cola, Colgate-Palmolive, and Lowe's—have announced dividend increases and reported earnings reflecting resilience amid economic challenges like tariffs and currency swings. Johns...
